@misc{10481/54458,
year = {2018},
month = {4},
url = {http://hdl.handle.net/10481/54458},
abstract = {Many patients previously using darunavir/ritonavir (DRV/r) (800/100mg) have switched to
darunavir/cobicistat (DRV/C) (800/150 mg) either as part of triple therapy (ART) or as monotherapy
with DRV (mDRV). The latter approach continues to be used in some countries for
patients receiving long-term treatment. However, to date, the behaviour of DRV/C in the
seminal compartment has not been analysed. This study explores how the combination
behaves in monotherapy, with respect to the control of viral load and seminal quality. To this
end, we studied 20 patients who were treated with mDRV/C after previous treatment with
mDRV/r for at least 24 weeks. A viral load control in seminal plasma similar to that published
in the literature was observed after 24 weeks of treatment with mDRV/C (viral load positivity
in 20% of patients). Similarly, semen quality was confirmed (70% normozoospermic) in
patients treated with this formulation, as has previously been reported for ART and mDRV/r.
The DRV levels measured in seminal plasma were above EC50, regardless of whether the
seminal viral load was positive or negative. We conclude that this mDRV/C co-formulation
behaves like mDRV/r in seminal plasma in terms of viral load control and semen quality.},
publisher = {Alan Winston, Imperial College London, UNITED KINGDOM},
title = {Effect of monotherapy with darunavir/ cobicistat on viral load and semen quality of HIV-1 patients},
author = {López Ruz, Miguel Ángel and López Zúñiga, Miguel Ángel and Gonzalvo, María Carmen and Samperdo, Antonio and Pasquau Liaño, Juan and Hidalgo, Carmen and Rosario, Javier and Castilla, Jose Antonio},
}